skip to main content

BRAF Inhibitor Photosensitivity — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardMelanoma & SkinBRAF Inhibitor PhotosensitivitySCE Medical Oncology

A patient receiving dabrafenib plus trametinib for BRAF V600-mutant melanoma develops a temperature of 38.4°C without hypotension, dehydration or infection. What is the SmPC-concordant first action?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Interrupt both drugs, evaluate the fever, and restart only after at least 24 hours symptom-free

Explanation lettering: B = shown as A · D = shown as B · E = shown as C · A = shown as D · C = shown as E

C is correct: at 38°C or above, dabrafenib is interrupted and, in combination treatment, trametinib is interrupted too; restart follows at least 24 hours symptom-free, at the same or a reduced dose according to severity/recurrence. A incorrectly continues full treatment; B ignores combination guidance; D is disproportionate for uncomplicated first pyrexia; E dose-reduces without the required interruption.

Reference: Tafinlar UK summary of product characteristics (Current UK SmPC, accessed August 2026): https://www.medicines.org.uk/emc/product/5190/smpc